[144] Akero Therapeutics, Inc. SEC Filing
Akero Therapeutics Form 144 filed for an insider sale of common stock. The notice reports an intended sale of 3,000 common shares with an aggregate market value of $142,371.90 from a total of 79,988,975 shares outstanding. The sale is listed for 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.
The filing shows the securities were acquired and exercised on 08/12/2025 via a stock option exercise and paid in cash. It also states "Nothing to Report" for any securities sold during the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Akero Therapeutics ha depositato il Form 144 per la vendita di azioni ordinarie da parte di un insider. L'avviso segnala l'intenzione di vendere 3,000 azioni ordinarie per un valore di mercato complessivo di $142,371.90 su un totale di 79,988,975 azioni in circolazione. La vendita 猫 prevista per il 08/12/2025 sul NASDAQ tramite Morgan Stanley Smith Barney LLC.
Il deposito indica che i titoli sono stati acquisiti ed esercitati il 08/12/2025 mediante un esercizio di stock option e pagati in contanti. Dichiara inoltre "Niente da segnalare" riguardo a titoli venduti negli ultimi tre mesi e contiene la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Akero Therapeutics present贸 el Form 144 por la venta de acciones ordinarias por parte de un insider. El aviso informa la intenci贸n de vender 3,000 acciones ordinarias por un valor de mercado agregado de $142,371.90 de un total de 79,988,975 acciones en circulaci贸n. La venta figura para el 08/12/2025 en el NASDAQ a trav茅s de Morgan Stanley Smith Barney LLC.
La presentaci贸n indica que los valores fueron adquiridos y ejercidos el 08/12/2025 mediante un ejercicio de opciones sobre acciones y pagados en efectivo. Tambi茅n declara "Nada que reportar" respecto a valores vendidos en los 煤ltimos tres meses e incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n material adversa no divulgada.
Akero Therapeutics臧� 雮措秬鞛� 氤错喌欤� 毵る弰毳� 鞙勴暣 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 韱奠靹滊姅 齑� 氚滍枆 欤检嫕 79,988,975欤� 欷� 3,000 氤错喌欤�鞚� 毵る弰 鞚橃偓毳� 氤搓碃頃橂┌, 齑� 鞁滉皜齑濎暋鞚� $142,371.90搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 毵る弰電� 08/12/2025鞐� NASDAQ鞐愳劀 Morgan Stanley Smith Barney LLC毳� 韱淀暣 鞚措（鞏挫 鞓堨爼鞛呺媹雼�.
鞁犼碃靹滌棎電� 頃措嫻 歃濌秾鞚� 08/12/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑 氚� 頄夓偓霅橃棃瓿� 顺勱笀鞙茧 歆�旮夒悩鞐堧嫟瓿� 鞝來榾 鞛堨姷雼堧嫟. 霕愴暅 歆�雮� 3臧滌洈 霃欖晥 韺愲Г霅� 歃濌秾鞐� 雽�頃� "氤搓碃頃� 靷暛 鞐嗢潓"鞚措澕瓿� 氇呾嫓頃橂┌, 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Akero Therapeutics a d茅pos茅 le Form 144 pour une vente d'actions ordinaires par un initi茅. L'avis signale l'intention de vendre 3,000 actions ordinaires pour une valeur marchande totale de $142,371.90 sur un total de 79,988,975 actions en circulation. La vente est pr茅vue le 08/12/2025 sur le NASDAQ via Morgan Stanley Smith Barney LLC.
Le d茅p么t indique que les titres ont 茅t茅 acquis et exerc茅s le 08/12/2025 au moyen d'un exercice d'options sur actions et pay茅s en 别蝉辫猫肠别蝉. Il pr茅cise 茅galement "Rien 脿 signaler" pour les titres vendus au cours des trois derniers mois et comprend la repr茅sentation standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Akero Therapeutics hat ein Form 144 f眉r den Insider-Verkauf von Stammaktien eingereicht. Die Mitteilung berichtet einen geplanten Verkauf von 3,000 Stammaktien mit einem aggregierten Marktwert von $142,371.90 aus insgesamt 79,988,975 ausstehenden Aktien. Der Verkauf ist f眉r den 08/12/2025 an der NASDAQ 眉产别谤 Morgan Stanley Smith Barney LLC verzeichnet.
Die Einreichung weist aus, dass die Wertpapiere am 08/12/2025 durch Aus眉bung von Aktienoptionen erworben und ausge眉bt und in Bargeld bezahlt wurden. Sie gibt au脽erdem "Nichts zu berichten" f眉r w盲hrend der letzten drei Monate verkaufte Wertpapiere an und enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.
- Full transaction details provided: class, share count, aggregate market value, broker, exchange, and trade date are listed
- Acquisition and payment disclosed: securities were acquired by a stock option exercise on 08/12/2025 and paid in cash
- No other sales reported in the past three months ("Nothing to Report")
- Broker identified: Morgan Stanley Smith Barney LLC is named as the executing broker
- None.
Insights
TL;DR: Small, disclosed insider sale of 3,000 shares executed same day as option exercise; routine Rule 144 filing.
The filing documents a single insider transaction: exercise of stock options and an intended sale of 3,000 Akero common shares valued at $142,371.90, to occur on 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The report indicates no other sales in the prior three months and includes the attestation regarding undisclosed material adverse information. For investors, this is a transparent, routine disclosure of an insider liquidity event rather than a corporate action or financial restatement.
TL;DR: Proper Rule 144 disclosure completed; key fields provided though some issuer relationship detail is absent.
The Form 144 provides required transaction details: class, quantity, market value, broker, trade date, and acquisition method (stock option exercise). The filer also confirms no recent sales. The form lists a blank for relationship to the issuer, which is a conspicuous omission in the issuer information section and may limit readers' ability to assess the seller's affiliation from this filing alone. Overall, the form fulfills basic Rule 144 disclosure requirements but lacks some contextual issuer relationship detail.
Akero Therapeutics ha depositato il Form 144 per la vendita di azioni ordinarie da parte di un insider. L'avviso segnala l'intenzione di vendere 3,000 azioni ordinarie per un valore di mercato complessivo di $142,371.90 su un totale di 79,988,975 azioni in circolazione. La vendita 猫 prevista per il 08/12/2025 sul NASDAQ tramite Morgan Stanley Smith Barney LLC.
Il deposito indica che i titoli sono stati acquisiti ed esercitati il 08/12/2025 mediante un esercizio di stock option e pagati in contanti. Dichiara inoltre "Niente da segnalare" riguardo a titoli venduti negli ultimi tre mesi e contiene la consueta dichiarazione che il venditore non 猫 a conoscenza di informazioni materiali sfavorevoli non divulgate.
Akero Therapeutics present贸 el Form 144 por la venta de acciones ordinarias por parte de un insider. El aviso informa la intenci贸n de vender 3,000 acciones ordinarias por un valor de mercado agregado de $142,371.90 de un total de 79,988,975 acciones en circulaci贸n. La venta figura para el 08/12/2025 en el NASDAQ a trav茅s de Morgan Stanley Smith Barney LLC.
La presentaci贸n indica que los valores fueron adquiridos y ejercidos el 08/12/2025 mediante un ejercicio de opciones sobre acciones y pagados en efectivo. Tambi茅n declara "Nada que reportar" respecto a valores vendidos en los 煤ltimos tres meses e incluye la representaci贸n est谩ndar de que el vendedor no conoce informaci贸n material adversa no divulgada.
Akero Therapeutics臧� 雮措秬鞛� 氤错喌欤� 毵る弰毳� 鞙勴暣 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 韱奠靹滊姅 齑� 氚滍枆 欤检嫕 79,988,975欤� 欷� 3,000 氤错喌欤�鞚� 毵る弰 鞚橃偓毳� 氤搓碃頃橂┌, 齑� 鞁滉皜齑濎暋鞚� $142,371.90搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 毵る弰電� 08/12/2025鞐� NASDAQ鞐愳劀 Morgan Stanley Smith Barney LLC毳� 韱淀暣 鞚措（鞏挫 鞓堨爼鞛呺媹雼�.
鞁犼碃靹滌棎電� 頃措嫻 歃濌秾鞚� 08/12/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑 氚� 頄夓偓霅橃棃瓿� 顺勱笀鞙茧 歆�旮夒悩鞐堧嫟瓿� 鞝來榾 鞛堨姷雼堧嫟. 霕愴暅 歆�雮� 3臧滌洈 霃欖晥 韺愲Г霅� 歃濌秾鞐� 雽�頃� "氤搓碃頃� 靷暛 鞐嗢潓"鞚措澕瓿� 氇呾嫓頃橂┌, 韺愲Г鞛愱皜 瓿店皽霅橃 鞎婌潃 欷戩殧頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Akero Therapeutics a d茅pos茅 le Form 144 pour une vente d'actions ordinaires par un initi茅. L'avis signale l'intention de vendre 3,000 actions ordinaires pour une valeur marchande totale de $142,371.90 sur un total de 79,988,975 actions en circulation. La vente est pr茅vue le 08/12/2025 sur le NASDAQ via Morgan Stanley Smith Barney LLC.
Le d茅p么t indique que les titres ont 茅t茅 acquis et exerc茅s le 08/12/2025 au moyen d'un exercice d'options sur actions et pay茅s en 别蝉辫猫肠别蝉. Il pr茅cise 茅galement "Rien 脿 signaler" pour les titres vendus au cours des trois derniers mois et comprend la repr茅sentation standard selon laquelle le vendeur n'est pas au courant d'informations d茅favorables importantes non divulgu茅es.
Akero Therapeutics hat ein Form 144 f眉r den Insider-Verkauf von Stammaktien eingereicht. Die Mitteilung berichtet einen geplanten Verkauf von 3,000 Stammaktien mit einem aggregierten Marktwert von $142,371.90 aus insgesamt 79,988,975 ausstehenden Aktien. Der Verkauf ist f眉r den 08/12/2025 an der NASDAQ 眉产别谤 Morgan Stanley Smith Barney LLC verzeichnet.
Die Einreichung weist aus, dass die Wertpapiere am 08/12/2025 durch Aus眉bung von Aktienoptionen erworben und ausge眉bt und in Bargeld bezahlt wurden. Sie gibt au脽erdem "Nichts zu berichten" f眉r w盲hrend der letzten drei Monate verkaufte Wertpapiere an und enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegten wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What did Akero Therapeutics (AKRO) report on Form 144?
How were the shares acquired according to the filing?
Does the Form 144 show other recent insider sales for AKRO?
Which broker is handling the sale in the AKRO Form 144?
What share count and outstanding shares are listed on the filing?
